Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/β-catenin pathway

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Abu Baker, A ^a   Laganiere, J ^a   Gaudet, R ^a   Rochefort, D ^a   Brais, B ^a   Neri, C ^b   Dion, P A ^a,c   Rouleau, G A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Beta catenin (b catenin); Lithium chloride (LiCl); Oculopharyngeal muscular dystrophy (OPMD); Poly (A) binding protein nuclear 1 (PABPN1); Wnt pathway

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; WNT PROTEIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; MOUSE; MYOTUBE; NONHUMAN; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WNT SIGNALING PATHWAY;

ANIMALS; BETA CATENIN; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GREEN FLUORESCENT PROTEINS; HUMANS; LITHIUM CHLORIDE; LYMPHOCYTES; MICE; MUSCULAR DYSTROPHY, OCULOPHARYNGEAL; MUTANT PROTEINS; MYOBLASTS; POLY(A)-BINDING PROTEIN I; PROTEIN TRANSPORT; TRINUCLEOTIDE REPEAT EXPANSION; WNT SIGNALING PATHWAY;

EID: 84887413610     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.342     Document Type: Article

References (60)

1. Dion P, Shanmugam V, Gaspar C, Messaed C, Meijer I, Toulouse A et al. Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice. Neurobiol Dis 2005; 18: 528-536
2. Boukriche Y, Maisonobe T, Masson C. Neurogenic involvement in a case of oculopharyngeal muscular dystrophy. Muscle Nerve 2002; 25: 98-101
3. Schober R, Kress W, Grahmann F, Kellermann S, Baum P, Gunzel S et al. Unusual triplet expansion associated with neurogenic changes in a family with oculopharyngeal muscular dystrophy. Neuropathology 2001; 21: 45-52
4. Brais B, Rouleau GA, Bouchard JP, Fardeau M, Tome FM. Oculopharyngeal muscular dystrophy. Semin Neurol 1999; 19: 59-66
5. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998; 18: 164-167
6. Abu-Baker A, Messaed C, Laganiere J, Gaspar C, Brais B, Rouleau GA. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum Mol Genet 2003; 12: 2609-2623
7. Bao YP, Cook LJ, O'Donovan D, Uyama E, Rubinsztein DC. Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J Biol Chem 2002; 277: 12263-12269
8. Wang Q, Mosser DD, Bag J. Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells. Hum Mol Genet 2005; 14: 3673-3684
9. Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O'Donovan DG et al. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med 2005; 11: 672-677
10. Chartier A, Raz V, Sterrenburg E, Verrips CT, van der Maarel SM, Simonelig M. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. Hum Mol Genet 2009; 18: 1849-1859
11. Davies JE, Rose C, Sarkar S, Rubinsztein DC. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy. Sci Transl Med 2010; 2: 34-40
12. Catoire H, Pasco MY, Abu-Baker A, Holbert S, Tourette C, Brais B et al. Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Hum Mol Genet 2008; 17: 2108-2117
13. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192-1205
14. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480
15. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781-810
16. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: Diseases and therapies. Nat Rev Genet 2004; 5: 691-701
17. Clevers H, Batlle E. EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res 2006; 66: 2-5
18. Lawrence PA, Struhl G, Casal J. Planar cell polarity: One or two pathways? Nat Rev Genet 2007; 8: 555-563
19. Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT. The Wnt/Ca2-pathway: A new vertebrate Wnt signaling pathway takes shape. Trends Genet 2000; 16: 279-283
20. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26
21. Ben-Ze'ev A. Cytoskeletal and adhesion proteins as tumor suppressors. Curr Opin Cell Biol 1997; 9: 99-108
22. Ben-Ze'ev A, Geiger B. Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer. Curr Opin Cell Biol 1998; 10: 629-639
23. Bullions LC, Levine AJ. The role of beta-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol 1998; 10: 81-87
24. Willert K, Nusse R. Beta-catenin: A key mediator of Wnt signaling. Curr Opin Genet Dev 1998; 8: 95-102
25. Semenov MV, Habas R, Macdonald BT, He X. SnapShot: Noncanonical Wnt signaling pathways. Cell 2007; 131: 1378
26. Dierick H, Bejsovec A. Cellular mechanisms of wingless/Wnt signal transduction. Curr Top Dev Biol 1999; 43: 153-190
27. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998; 14: 59-88
28. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 2003; 10: 1255-1266
29. Kleber M, Sommer L. Wnt signaling and the regulation of stem cell function. Curr Opin Cell Biol 2004; 16: 681-687
30. Eldar-Finkelman H. Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol Med 2002; 8: 126-132
31. Woodgett Jr. Judging a protein by more than its name: GSK-3. Sci STKE 2001; 2001: Re12
32. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359(Pt 1): 1-16
33. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002; 22: 373-384
34. Pasco MY, Catoire H, Parker JA, Brais B, Rouleau GA, Neri C. Cross-Talk between canonical Wnt signaling and the sirtuin-FoxO longevity pathway to protect against muscular pathology induced by mutant PABPN1 expression in C. elegans. Neurobiol Dis 38: 425-433
35. Freeman MP, Freeman SA. Lithium: Clinical considerations in internal medicine. Am J Med 2006; 119: 478-481
36. Dubovsky SL. Treatment of bipolar depression. Psychiatr Clin North Am 2005; 28: 349-370, vii
37. Cohen P, Yellowlees D, Aitken A, Donella-Deana A, Hemmings BA, Parker PJ. Separation and characterisation of glycogen synthase kinase 3, glycogen synthase kinase 4 and glycogen synthase kinase 5 from rabbit skeletal muscle. Eur J Biochem 1982; 124: 21-35
38. Woodgett Jr. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990; 9: 2431-2438
39. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998; 9: 2081-2084
40. Messaed C, Dion PA, Abu-Baker A, Rochefort D, Laganiere J, Brais B et al. Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy. Neurobiol Dis 2007; 26: 546-557
41. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. Green fluorescent protein as a marker for gene expression. Science 1994; 263: 802-805
42. Heim R, Cubitt AB, Tsien RY. Improved green fluorescence. Nature 1995; 373: 663-664
43. Gumbiner BM. Carcinogenesis: A balance between beta-catenin and APC. Curr Biol 1997; 7: R443-R446
44. Stambolic V, Ruel L, Woodgett Jr. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668
45. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-3804
46. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylationregulated ubiquitination and degradation of beta-catenin. J Biol Chem 1997; 272: 24735-24738
47. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459
48. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349-352
49. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001; 41: 789-813
50. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS. Activation of the Wnt signaling pathway: A molecular mechanism for lithium action. Dev Biol 1997; 185: 82-91
51. Pecina-Slaus N. Wnt signal transduction pathway and apoptosis: A review. Cancer Cell Int 2010; 10: 22
52. Sadoul R. Bcl-2 family members in the development and degenerative pathologies of the nervous system. Cell Death Differ 1998; 5: 805-815
53. Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: Can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 2004; 16: 83-90
54. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 281: 1322-1326
55. Cossu G, Borello U. Wnt signaling and the activation of myogenesis in mammals. EMBO J 1999; 18: 6867-6872
56. Polesskaya A, Seale P, Rudnicki MA. Wnt signaling induces the myogenic specification of resident CD45-Adult stem cells during muscle regeneration. Cell 2003; 113: 841-852
57. Korkut C, Budnik V. WNTs tune up the neuromuscular junction. Nat Rev Neurosci 2009; 10: 627-634
58. Verhees KJ, Schols AM, Kelders MC, Op den Kamp CM, van der Velden JL, Langen RC. Glycogen synthase kinase-3beta is required for the induction of skeletal muscle atrophy. Am J Physiol Cell Physiol 2011; 301: C995-C1007
59. van der Velden JL, Langen RC, KeldersMC, Wouters EF, Janssen-Heininger YM, Schols AM. Inhibition of glycogen synthase kinase-3 beta activity is sufficient to stimulate myogenic differentiation. Am J Physiol Cell Physiol 2006; 290: C453-C462
60. Terracciano C, Nogalska A, Engel WK, Askanas V. In A beta PP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: Effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem 2010; 112: 389-396